Xbrane Biopharma

Company Description

---

Xbrane Biopharma was founded at Stockholm University 2008 by researchers Jan-Willem De Gier and Samuel Wagner together with Serendipity Ixora, run by the entrepreneurs Saeid Esmaeilzadeh and Ashkan Pouya.

The foundation of the company was a unique technology that resulted in a more cost-effective production of proteins in host cells of the form E.coli.

Xbrane’s first years were about establishing the technology platform, patent protect it and establishing the required capabilities and know-how within the organization. This was done through close collaboration with leading companies engaged in production of proteins and enzymes, where Xbrane’s technology could be applied. Many of these customers were in the pharmaceutical industry, which led the company to relatively quickly realize where the focus should be. Xbrane worked during this period with leading pharmaceutical companies, among others with MedImmune (part of AstraZeneca).

Year founded

---

2008

Served area

---

Worldwide

Headcount

---

74

Headquarters

---

Retzius väg 8, 17165 Solna – Sweden

Shares outstanding

---

15,415,199

IPO

---

Sept. 1, 2019

Stock exchange(s)

---

Nasdaq Stockholm